|Bid||38.00 x 1000|
|Ask||42.41 x 800|
|Day's range||40.39 - 42.01|
|52-week range||36.48 - 55.43|
|Beta (5Y monthly)||0.76|
|PE ratio (TTM)||39.44|
|Earnings date||09 Aug 2021 - 13 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||47.33|
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference as follows:
At this time, I'd like to welcome everyone to Eagle Pharmaceuticals' First Quarter 2021 Financial Results Call. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals.
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -66.67% and -9.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?